Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56 Case report

Main Article Content

Krzysztof Trzebiński

Abstract

The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Trzebiński K. Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56. OncoReview [Internet]. 2023Apr.1 [cited 2024May26];13(1(49):27-0. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/2791
Section
SUPPORTIVE CARE IN ONCOLOGY

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49. http://doi.org/10.3322/caac.21660.
2. Didkowska J, Wojciechowska U, Olasek P et al. Nowotwory złośliwe w Polsce w 2019 roku. Warszawa 2021.
3. Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378: 1408-18. http://doi.org/10.1056/NEJMoa1715546.
4. Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31: 1119-34. http://doi.org/10.1016/j.annonc.2020.06.011.
5. Howard LE, Moreira DM, De Hoedt A et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017; 120(5B): E80-6. http://doi.org/10.1111/bju.13856.